NDC 0069-0308-01
Trazimera 150 mg/7.15mL
trastuzumab-qyyp · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Trazimera is a prescription injection used to treat HER2-positive breast cancer and gastric cancer by blocking the HER2 protein that helps cancer cells grow. It is given intravenously and belongs to a class of drugs called HER2/neu receptor antagonists.
Key Facts
- Brand Name
- Trazimera
- Generic Name
- trastuzumab-qyyp
- NDC Code (Package)
0069-0308-01- NDC Code (Product)
0069-0308- Manufacturer
- Pfizer Laboratories Div Pfizer Inc
- Strength
- 150 mg/7.15mL
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761081
- Drug Class
- HER2/neu Receptor Antagonist [EPC]
- Marketing Start
- 03/10/2021
Recall History
No Recall HistoryView Full Drug Page
Trazimera — All PackagesNot medical advice. This information is for reference only. Always consult your doctor or pharmacist.